Published in Clin Nucl Med on June 01, 1999
How many sentinel lymph nodes are enough for accurate axillary staging in t1-2 breast cancer? J Breast Cancer (2011) 0.85
Multimodal sentinel lymph node mapping with single-photon emission computed tomography (SPECT)/computed tomography (CT) and photoacoustic tomography. Transl Res (2011) 0.83
Sentinel nodes. Interval nodes, lymphatic lakes, and accurate sentinel node identification. Clin Nucl Med (2000) 0.77
Guideline for the management of breast lumps. Can J Surg (1998) 4.02
neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol (1998) 2.42
Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism (2000) 2.30
A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ (2001) 2.11
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol (1999) 1.92
Adjuvant interferon therapy for patients at high risk for recurrent melanoma: an updated systematic review and practice guideline. Clin Oncol (R Coll Radiol) (2012) 1.62
Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol (1999) 1.42
Adverse events in nuclear medicine - cause for concern? Eur J Nucl Med Mol Imaging (2012) 1.41
31P changes as a measure of therapy response in human osteosarcomas implanted into nude mice. Magn Reson Imaging (1994) 1.40
Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk or extremities. Clin Oncol (R Coll Radiol) (2011) 1.39
Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res (2001) 1.39
Cerebral neutrophil recruitment, histology, and outcome in acute ischemic stroke: an imaging-based study. Stroke (2004) 1.14
A study of doxorubicin loading onto and release from sulfopropyl dextran ion-exchange microspheres. J Control Release (2001) 1.07
Noninvasive quantification of dopamine D2 receptors with iodine-123-IBF SPECT. J Nucl Med (1996) 1.04
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer (2000) 0.93
99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer. Nucl Med Commun (1999) 0.92
Susceptibility artifact reduction in fat suppression. Magn Reson Med (1995) 0.90
Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med (1998) 0.88
Imaging inflammation with 99Tcm-labeled chemotactic peptides: analogues with reduced neutropenia. Nucl Med Commun (1996) 0.88
Clinical use of technetium-99m HM-PAO for determination of brain death. J Nucl Med (1989) 0.88
Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm (2001) 0.87
SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology (1999) 0.87
Routine determination of radiochemical purity of 99mTc-MIBI. Int J Rad Appl Instrum A (1989) 0.86
Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer. Ann Surg Oncol (1996) 0.84
Physiologic modeling of PET data: quantitative conflict and challenge. J Nucl Med (1997) 0.84
On size, distance, and visual angle perception. Percept Psychophys (1985) 0.84
Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. J Nucl Med (1997) 0.83
Evaluating the organization and delivery of breast cancer services: use of performance measures to identify knowledge gaps. Breast Cancer Res Treat (2006) 0.83
Variation in lymphatic function may predispose to development of breast cancer-related lymphoedema. Eur J Surg Oncol (2004) 0.82
SPECT imaging of dopamine receptors. J Nucl Med (1996) 0.82
Moon illusions redescribed. Percept Psychophys (1986) 0.82
Malignant melanoma in a patient with oculocutaneous albinism. J Cutan Med Surg (2000) 0.82
Comparison of (99m)Tc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function. Br J Cancer (2001) 0.81
Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer (1999) 0.81
Elevated levels of plasma triglycerides are associated with histologically defined premenopausal breast cancer risk. Nutr Cancer (1997) 0.80
The clearance kinetics of autologous RhD-positive erythrocytes coated ex vivo with novel recombinant and monoclonal anti-D antibodies. Clin Exp Immunol (2007) 0.80
From graphical analysis to multilinear regression analysis of reversible radioligand binding. J Cereb Blood Flow Metab (1996) 0.80
BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med (2000) 0.80
Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data. J Nucl Med (1999) 0.80
Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys (1998) 0.79
Radiochemical purity of [99mTc]HM-PAO. J Nucl Med (1988) 0.79
Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med (1993) 0.79
Labelling small quantities of monoclonal antibodies and their F(ab')2 fragments with technetium-99m. Nucl Med Biol (1995) 0.79
Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans. Ann Nucl Med (1993) 0.79
Lymphatic transfer studies with immunoglobulin scintigraphy after axillary surgery. Eur J Surg Oncol (2007) 0.79
Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med (2000) 0.78
Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med (1997) 0.78
In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors. Cancer Biother Radiopharm (2000) 0.77
A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphy. Br J Urol (1995) 0.77
Dose-response curves for edrophonium, neostigmine, and pyridostigmine after pancuronium and d-tubocurarine. Anesthesiology (1987) 0.77
Tissue-to-blood transport of radiolabelled immunoglobulin injected into the web spaces of the hands of normal subjects and patients with breast cancer-related lymphoedema. J Vasc Res (2004) 0.77
A pilot study of dual-isotope lymphoscintigraphy for breast sentinel node biopsy comparing intradermal and intraparenchymal injection. Eur J Surg Oncol (2009) 0.76
Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: effect of lipophilicity. Bioconjug Chem (2000) 0.76
Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl Med Biol (2001) 0.76
Appropriate procedures for the safe handling and pathologic examination of technetium-99m-labelled specimens. CMAJ (2001) 0.75
BMS181321 accumulation in rodent and human cells: the role of P-glycoprotein. Br J Cancer Suppl (1996) 0.75
Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experience. Clin Nucl Med (1990) 0.75
A kit for labelling erythrocytes or leukocytes with technetium-99m. Int J Rad Appl Instrum B (1990) 0.75
Role of NADPH:cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia. Biochem Pharmacol (2000) 0.75
Cerebral perfusion imaging. J Nucl Med (1987) 0.75
Neostigmine, pyridostigmine and edrophonium as antagonists of deep pancuronium blockade. Can J Anaesth (1987) 0.75
A potentially artifact-free oral contrast agent for gastrointestinal MRI. Magn Reson Med (1993) 0.75
Optimized radiolabelling of pig granulocytes with indium-111 tropolonate. Int J Rad Appl Instrum B (1990) 0.75
External radioactive reference markers in SPECT imaging of the dopamine system. J Nucl Med Technol (1999) 0.75
Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Breast Cancer Res Treat (1998) 0.75
In vivo animal tests of an artifact-free contrast agent for gastrointestinal MRI. Magn Reson Imaging (1997) 0.75
Mechanisms that contribute to the in vitro relaxation and signal intensity of water in barium sulfate suspensions used as MRI contrast agents. Magn Reson Imaging (1993) 0.75
Accumulation of sestamibi in lymphoma cell lines in vitro. Leuk Lymphoma (2000) 0.75
Power efficient on-resonance saturation pulses for magnetization transfer in magnetic resonance imaging. Magn Reson Med (1996) 0.75
A solid-phase technique for preparation of no-carrier-added technetium-99m radiopharmaceuticals: application to the streptavidin/biotin system. Nucl Med Biol (2000) 0.75
Synthesis and characterization of surface-hydrophobic ion-exchange microspheres and the effect of coating on drug release rate. J Pharm Sci (2000) 0.75
Decomposition of Tc-99m pyrophosphate by peroxides in pertechnetate used in preparation. J Nucl Med (1981) 0.75
In vitro comparison of HMPAO and gentisic acid for labelling leukocytes with 99mTc. Eur J Nucl Med (1990) 0.75
A novel amine-dioxime chelator for technetium-99m: synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells. Bioconjug Chem (2000) 0.75
The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat (2006) 0.75
Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia. Bioconjug Chem (1999) 0.75
Evaluation of reduction-mediated labelling of antibodies with technetium-99m. Int J Rad Appl Instrum B (1992) 0.75
Nuclear medicine detection of inflammation and infection. Curr Opin Radiol (1991) 0.75
Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics. Biochem Pharmacol (1997) 0.75
Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technology. Bioconjug Chem (1999) 0.75